Navigation Links
New Study Shows Impressive Results with Abutment-Free Sophono System
Date:2/7/2013

3.    No pain or skin complications

4.    Statistical and clinical improvement in speech-in-noise, an indication of how well the children could understand speech in a noisy environment

Study authors were: Françoise Denoyelle, M.D., Ph.D.; Nicolas Leboulanger, M.D., Ph.D.; Cyrille Coudert; Olivia Mazzaschi, M.D.; Natalie Loundon, M.D.; Eric Vicaut; Natacha Tessier; and Eréa-Noël Garabedian, M.D.

“The results that the article presents confirm the hearing performance Sophono continually sees with those using the Sophono Alpha System – in terms of hearing ability, speech understanding and high levels of satisfaction,” says Jim Kasic, president and CEO of Sophono. “Children, in particular, benefit from Sophono’s abutment-free technology.”

Sophono, Inc. (http://www.sophono.com)
Sophono, Inc., is a medical device manufacturer specializing in implantable, bone conduction hearing devices. The company’s products are designed for individuals suffering from severe to profound hearing loss or impairment. The Sophono Alpha 2™ System is the only abutment-free, implantable, bone-anchored hearing system available today. Treating those with conductive hearing loss, mixed hearing loss, and single-ear deafness, the FDA-cleared Alpha 2 device eliminates the problematic abutment of devices by using magnets to affix external sound processors.

Sophono corporate headquarters and manufacturing operations reside in Boulder, Colo. The company maintains an office in Germany, works with more than 20 distributors, and is actively selling in more than 30 countries.

(end)

Read the full story at http://www.prweb.com/releases/2013/2/prweb10405031.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. EU Study Finds UK Health Product Benefit Metric Flawed
2. Notre Dame study explores the potential benefits and threats of nanotechnology research
3. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
4. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
5. Wysebridge Launches Patent Bar Exam Study Review
6. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
7. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
8. Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics Human Pilot Study
9. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
10. Study identifies targeted molecular therapy for untreatable NF1 tumors
11. Study Finds Proof of Acupuncture Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
(Date:12/12/2014)... (PRWEB) December 11, 2014 Graphite Metallizing ... materials for pumps and process equipment, has appointed Kirk ... States and Ontario, Canada. Staller holds a B.S. degree ... in the industrial market place, much of it with ... out of his Michigan office. , “We are ...
(Date:12/12/2014)... Electronic Data Interchange (EDI) has ... and supply chain management to depend from paper ... benefits associated with the use of EDI such ... has helped improve the acceptance of this technology ... data tables and 107 figures spread through 210 ...
(Date:12/12/2014)... 2014 LayerBio is an MIT ... and wound care applications. The National Science ... business innovation research grant to support development of ... leading cause of irreversible blindness worldwide. In the ... from glaucoma. The typical first-line treatment for ...
Breaking Biology Technology:Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 3The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 4MIT Spinoff Receives NSF Grant to Develop Nanoparticle Glaucoma Therapy 2
... Than rituximab ... in a Pre-Clinical Study, ... that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing complement dependent cytotoxicity ... study. The CD20,antibodies were incubated with tumor cells and analyzed ...
... Prize winner Richard Feynman presented a talk entitled There,s Plenty ... was no physical reason why humans couldn,t manipulate atoms. ... the new atom positions remains. How do you know ... 7, 2007 issue of Science, IBM and Imago have taken ...
... Chief Financial Officer and James Weaver as Chairman, ... ILI ) announced today that Thomas Gerson has been ... Weaver as,Chairman of the Board of Directors. In addition, ... and Development. "We are pleased to welcome Tom ...
Cached Biology Technology:Genmab Announces Encouraging Preclinical Data for ofatumumab 2IBM and Imago find a crucial difficulty in semiconductor device scaling 2Interleukin Genetics Announces Management and Board Appointments 2Interleukin Genetics Announces Management and Board Appointments 3Interleukin Genetics Announces Management and Board Appointments 4
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Six researchers from the Technische Universitaet Muenchen are ... bring around ten million euros to support pioneering ... investigate the impact of extreme weather events on ... magnetic vortices for enhanced data processing. Prof. Rdiger ...
... among South Asians to be recalculated has been published by ... from the University,s Departments of Health Sciences and Cardiovascular Sciences ... Asians should be classed as obese to be redefined. ... a journal of the Public Library of Science. South ...
... 2004 as a three-person start-up may well be on ... Advanced by a team of young Dutch scientists pushing ... is attracting the attention of some key investors and ... to innovative SMES, with the Eurostars funding programme leading ...
Cached Biology News:10 million euros for pioneering research projects at TU Muenchen 210 million euros for pioneering research projects at TU Muenchen 310 million euros for pioneering research projects at TU Muenchen 410 million euros for pioneering research projects at TU Muenchen 510 million euros for pioneering research projects at TU Muenchen 610 million euros for pioneering research projects at TU Muenchen 7New research calls for lower limit to be set for South Asian obesity level 2Biotech start-up brings DNA-sequencing to the medical market 2Biotech start-up brings DNA-sequencing to the medical market 3
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
...
Biology Products: